Summary Methionine (MET)-dependent cell lines require MET to proliferate, and homocysteine (HCY) does not act as a substitute for this requirement. From six O6-methylguanine-DNA methyltransferase (MGMT)-efficient (mer) cell lines tested, two medulloblastomas (Daoy and D-341) and a lung non-small-cell adenocarcinoma with metastatic potential (H-1623) were most sensitive to MET deprivation, while two glioblastomas (U-138, D-263) and a small-cell lung carcinoma H-1944 were moderately to weakly dependent. Regardless of the degree of MET dependence, all of these lines down-regulated their MGMT activity within 48-72 h of transfer from MET+HCY-to MET-HCY+ media, long before the eradication of the culture. Reduction of MGMT activity was due to a decline of both MGMT mRNA and protein levels. However, the reduction was not related to the methylation status of the MGMT promoter at the Smal site or the Hpall sites in the body of the gene; such sites have been shown to be associated in MGMT regulation and in defining the mer phenotype. MET-dependent, met tumour cells cultured in MET-HCY+ were more sensitive to BCNU (IC50 = 5-1 0 gIM) than those cultured in MET+HCY-(IC50 = 45-90 gM), while MET-independent or mer cell lines were unaffected. This indicates that reduction of MGMT, imposed by the absence of MET, renders mer tumour cells more susceptible to alkylating agents. The relatively selective suppression of MGMT activity in mer MET-dependent tumour cells, in combination with the inability of such cells to proliferate in the absence of MET, may lead to the development of more effective treatment strategies for mer MET-dependent tumours.
Methionine (MET) is essential for normal growth and development of mammals. This amino acid participates in protein synthesis (Tautt et al, 1982) ; numerous S-adenosylmethionine-dependent transmethylation reactions (Stem and Hoffman, 1984) ; the formation of polyamines spermidine and spermine (Pegg 1984) ; synthesis of cystathionine, cysteine and other metabolites of the transulphuration pathway; the supply of homocysteine (HCY), which is needed for metabolism of intracellular folates; and the catabolism of choline (Finkelstein, 1990) . With very few exceptions, normal cells can use HCY in place of MET to support all of the above reactions (Hoffman, 1990; Guo et al, 1993a) . In contrast to normal cells, a large number of cultured tumour cells and about 25% of fresh human tumours grown in histocultures cannot effectively use HCY in place of MET, and such cells or tumours are classified as MET-dependent (Guo et al, 1993a,b) . There is substantial evidence that MET dependence occurs more frequently in metastatic tumour cells (Breillout et al, 1987 (Breillout et al, , 1990 Liteplo, 1990) , although reversion of dependence is not necessarily linked to loss of metastatic potential (Vanhamme and Szpirer, 1989) . The biochemical basis for MET dependency is not yet fully understood. MET-dependent tumour cells appear to synthesize MET from HCY by an active MET synthase, but at levels not adequate to both sustain growth and meet their high transmethylation requirements (Judde et al, 1989) . The most likely biochemical defect leading to MET dependency is thought to be related to the synthesis and availability of methylcobalamine, which is directly involved in the transfer of methyl groups from 5-methyltetrahydrofolate to HCY (Liteplo et al, 1991; Fiskerstrand et al, 1994) .
The defect in the use of HCY has been extensively investigated to induce selective killing of tumours while sparing normal tissues. Lack of MET results in a reversible blockage of rapidly proliferating tumour cells in the late S and G2 phases of the cell cycle (Stem and Hoffman, 1986; Guo et al, 1993a) . In general, cells arrested in S, G2 or M are not only susceptible to spontaneous death, unlike cells arrested in G1, but they are also supersensitive to various chemotherapeutic drugs, such as doxorubicin, which blocks and kills in G2 (Stem and Hoffman, 1986) . MET-depleting diets in combination with chemotherapy suppress metastasis of Yoshida sarcoma and rhabdomyosarcoma tumours in animals (Breillout et al, 1987; Goseki et al, 1992) . Potentiation of many drugs, some of which act by damaging cellular DNA, indicates that MET deprivation may compromise DNA repair ability in addition to causing premitotic cell cycle blocks and cell death in tumours. The modulation of resistance of tumour cells to chemotherapy may encompass a large number of mechanisms including those involved in the processing of the agent (metabolism, conjugation, etc.), its transport into or its elimination from the target cell, or the reversal or repair of the damage induced by such agents. A systematic study of the modulation of such mechanisms by deprivation of MET will allow the deployment of the full potential of the MET-dependence phenotype in the treatment of several tumours. In that context, we examined the effect of MET depletion on the ability of tumour cells to repair 06-alkylguanine adducts by 06-methylguanine-DNA methyltransferase (MGMT).
Such adducts are major contributors to the toxicity of alkylating anti-tumour agents, such as procarbazine, temozolomide, carmustine and related nitrosoureas commonly used for the treatment of several tumours (Schold et al, 1989; Dunn et al, 1991; Egyhazi et al, 1991; Brent et al, 1993; Marathi et al, 1993) .
METHODS

Cell culture
NIH/3T3 from American Type Culture Collection (ATCC Rockville, MD, USA) was used as a negative control for MET dependence. SWB-40 and U-87, both mer-human anaplastic glioma cell lines, were used to determine the effect of MET depletion on BCNU resistance by mechanisms other than those that are MGMT mediated. The effect of MET deprivation on cell growth and MGMT levels was examined in Daoy and D-341 (human medulloblastomas), U-138 and D-263 (human glioblastomas), H-1994 (a human small-cell lung carcinoma) and H-1623 (a human non-small-cell lung adenocarcinoma with metastatic ability). The brain tumour cell lines were obtained either from ATCC (U-138, Daoy, U-87) or were donated by Dr H Friedman (Department of Pediatrics, Duke University) (D-341, D-263) . The lung tumour cell lines were donated by Dr A Gazdar (Department of Pathology, UT Southwestem) and were adapted to our medium. All cells were maintained in culture in Eagle's minimum essential medium (Gibco) supplemented with lysine, valine and leucine (100 gM each) and with 10% dialysed MET-free fetal bovine serum. The medium was also supplemented with non-essential amino acids (1:100 dilution of stock from Gibco), 1 mm sodium pyruvate, sodium bicarbonate, 6.0 gM a-hydroxycobalamin, 100 jiM folic acid, 0.2 mg ml-gentamicin and either 100 jM L-MET (MET+HCY-) or 200 jM D,L-HCY thiolactone (MET-HCY+). Cells were plated in MET+HCY-medium and were allowed to attach and grow until they reached 50% confluency (6 x 106 per flask). Detaching cells ascertained to be dead by trypan blue exclusion were removed by changing the medium every 48 h. Cells were then either trypsinized and reseeded in the same medium or washed with PBS and supplied with the MET-HCY+ medium. Because of extensive death in this medium, it was necessary to remove detaching dead cells on a daily basis. Cells from both media were harvested at time intervals indicated and used to measure cell cycle status and MGMT activity. Cells from either cultures (5 x 107) were also harvested, washed with PBS and immediately frozen as a source of protein, DNA and RNA. All cells collected were live (>95%) as determined by trypan blue exclusion.
Staining for DNA analysis
Trypsinized cells were washed with PBS three times and spread on slides with a cytospin centrifuge at 500 r.p.m. for 1 min. Slides were dipped in Fix-Rite for 1 min, washed with water and 1 N hydrochloric acid and incubated in preheated hydrochloric acid at 60°C for 15 min. The slides were rinsed with water, stained with Schiff's reagent for 45 min at room temperature, treated with two successive changes of freshly prepared sulphurous acid, rinsed well and dehydrated. Finally, slides were cover-slipped for DNA analysis. DNA content was measured by image analysis using a V-I 470 Optronics camera and Bio-Quant system IV software. Three to four hundred cells were measured in each slide and the distribution, based on DNA content, was determined with Lotus 123 software. A control of normal lymphocytes was used to assign DNA content values. MET-dependent cell cycle blocks (MDCCB) were determined according to Guo et al (1993a) 
DNA probes
MGMT cDNA was derived by polymerase chain reaction (PCR) of the cloned insert in the plasmid pKT100 (Tano et al, 1990 ) using #1201 and #1211 sequencing primers (New England Biolabs, Beverly, MA, USA) with a GeneAmp kit (Perkin Elmer Cetus, Norwalk, CT, USA) using the starting parameters recommended by the manufacture. Twenty-five cycles of amplification were carried out, with each cycle consisting of 30 s at 94°C, 1 min at 45°C and 1 min at 72°C. A 772-bp sequence from the MGMT promoter was obtained by restriction of the plasmid pKT200 (Harris et al, 1991) with Sstl (Gibco-BRL, Gaithersburg, MD, USA) and Pstl (New England Biolabs) and excision of the fragment from low-melting point agarose gel.
Northern Analysis
Total RNA was prepared from frozen cells by lysing them in RNAzol (Tel-Test, Friendswood, TX, USA) according to the manufacturer's protocol. RNA (10 jg) was size fractionated in 1% agarose gels containing 2.2 M formaldehyde (Fisher, Fair Lawn, NJ, USA) (Sambrook et al, 1989 ) and transferred to nylon membranes (Duralon-UV, Stratagene, La Jolla, CA, USA) by capillary blotting. RNA was covalently attached with UV and prehybridized for 4 h at 42°C in 50% formamide, 5 x SSPE (0.18 M sodium chloride, 0.01 M sodium phosphate, 1 mm EDTA), 5 x Denhardt's solution (Sambrook et al, 1989) , 7.5% dextran sulphate, 1.5% sodium dodecyl sulphate (SDS), and 200 jg ml-' of sheared salmon sperm DNA. Hybridization was conducted with 32P-labelled MGMT cDNA probe for 20 h at 42°C. Unbound probe was removed by washing membranes twice with 200 ml of 2 x SSC (0.015 M sodium chloride, 0.0015 M sodium citrate) for 15 min at room temperature, followed by washing twice with 200 ml of 0.1 x SSC, 0.1% SDS for 15 min at 65°C. Membranes were exposed to X-Omat AR Kodak film at -70°C, and RNA was quantitated. Membranes were reprobed with GAPDH cDNA (Clontech, Palo Alto, CA, USA) to control for equal loading and transfer. After this hybridization, membranes were washed as before except that the final step was performed at 68°C instead of 65°C.
Analysis of MGMT gene methylation
Ten micrograms of genomic DNA from each cell line, isolated according to protocol 1 of Sambrook et al (1989) was restricted with S U jig-' of EcoRI and HpaII (New England Biolabs) for 4-6 h and then restricted again with the same amount of enzyme overnight. Electrophoresis of the samples in a 0.7% agarose gel containing 0.5 x TBE at 22 V for 18 h was followed by alkaline denaturation and neutralization, according to Sambrook et al (1989) , and capillary blotting onto a nylon membrane as in Northern analysis and covalent linking of the DNA using UV light. The blot was hybridized with a 32P-labelled MGMT cDNA probe and washed as described for Northern analysis before autoradiography for 2 days at -70°C with intensifying screens.
Analysis of MGMT promoter methylation
Methylation of the 5'-untranslated region of the MGMT gene was investigated by Southern analysis using the methylation-sensitive restriction enzyme SmaI (Promega, Madison, WI, USA). Genomic DNA was restricted with 5 U jg-I of enzyme at 37°C (25°C for SmaI) for 4-6 h and then restricted again with the same amount of enzyme overnight. Southern analysis was performed using the 772-bp probe from the 5'-untranslated region.
Cytotoxicity assays
The cytotoxicity of BCNU on cultured cells in MET+HCY-and MET-HCY+ was measured by a modification of the method of Branch et al (1993) as follows: MET-dependent cells were seeded and cultured in MET+HCY-in 35-mm Petri dishes until they were nearly confluent. The cells were then transferred in MET-HCY+ and cultured for an additional 4-6 days at which time cell numbers were reduced because of cell death and inhibition of mitosis. Dead cells were removed and medium was replaced on a daily basis.
Following this period in MET-HCY+ medium, remaining live cells were washed with PBS and then treated with various concentrations of BCNU in PBS for 1 h at 37°C while they were still attached. Subsequently, the' BCNU was removed, replaced with MET+HCY-medium, and cultures were incubated for an additional 4 days at 37°C in 6% carbon dioxide. At that time cells were trypsinized and counted using a Coulter-Counter (Coulter Electronics, Hialeah, FI, USA). The concentration of the drug that halves the growth rate of the tumour cells (IC50) was determined from plots of BCNU concentrations vs the per cent change in cell numbers compared with untreated controls within a 4-day interval from treatment (Jackson, 1992) . The IC50 of BCNU on METdependent cells cultured in MET+HCY-or MET-independent cells cultured in either media was also determined by the same method. With such cultures, however, cell numbers originally seeded were adjusted to yield cell densities that were similar to those of MET-HCY+ cultures at the time of treatment with BCNU. of cell loss in MET-HCY+ cultures was indicative of at least two different mechanisms of toxicity. Examination of cell cycle kinetics indicated the accumulation in late S and G2 at day 2 from transfer to MET-deficient media (Figure 2) , which was characteristic of a G2 cell cycle block. Cell cycle kinetic analysis for the Daoy, U-138, H-1632 and D-341 is shown in Table 1 . MET-dependent G2 cell cycle blocks (MDCCB<0.8) were observed in all of these four lines, but they were not detectable in H-1944, SWB-40 and D-263, which were moderately to weakly dependent on MET. A G2 block was imposed earlier in H-1623, D-341 and Daoy than in U-138 and was generally followed by a massive detachment and death of cells (Figure 1 ) and a concomitant increase of the MDCCB (Table 1) . Following the G2 block and elimination of G2-arrested cells, the mitotic index declined rapidly by more than an order of magnitude below the control value as the MDCCB number increased above one, indicating that surviving cells did not cycle and were most probably checked at G,. MDCCB fluctuations consistent with G2 or GI blocks were not found in NIH-3T3 or U-87 which were not MET dependent and proliferated in MET-HCY+. Cell cultures of MET-dependent cells tested here could be rescued, even after elimination of more than 95% of the original cell population, by replenishing MET in the medium. Karyotypic analysis before MET depletion, and also 48 h after the repletion of MET in a Daoy culture deprived of MET for ten days, indicated that no additional chromosomal aberrations or selection of a resistant cell population were introduced by this treatment. In all cell lines tested, repletion of MET in the medium resulted in the recovery of both cell proliferation capacity and base line MGMT activity. In Daoy, recovery of the MGMT activity was not complete 48 h (65% of the base line) from repletion of MET following a 10-day culture period in HCY (DM Kokkinakis, unpublished observations). At that time cells had recovered their ability to divide and proliferated with a doubling time of 22 h.
RESULTS
Reduction of MGMT activity in tumour cells by methionine depletion
The native MGMT activities of the cell lines tested here are shown in Table 2 . These activities were not affected by serum withdrawal and the associated inhibition of growth for up to 72 h, and they were not dependent on the state of confluency of the culture (data not shown). A cell cycle-dependent regulation of MGMT activity, previously suggested (Dunn et al, 1986 ) by serum starvation synchronization, was also not evident in these lines. However, MGMT activities were dependent on the presence of MET in the culture medium (Table 2) . With the exception of NIH-3T3 cells, which were not MET dependent, MGMT activity declined with a half-life ranging from 24 to 48 h after cells were transferred to MET-HCY+ media and reached a nadir of 25-40 fmol mg-' protein in all the lines tested. Levels of MGMT activity remained low in MET-dependent cells as long as such cells remained alive in the MET-HCY+ medium. In Daoy, the decline in the MGMT activity in MET-HCY+ was due to the reduction of MGMT protein (Figure 3) . The amount of MGMT protein determined by densitometric scanning 6 days after culturing in MET-HCY+ was reduced eightfold, which was similar to the decline of MGMT activity. Northern analysis (Figure 4) reduced to approximately 5 ,UM when cells were cultured in MET-HCY+ for 4 days before the exposure to BCNU ( Figure 6A ). In comparison, the resistance of the mer-, MET-dependent SWB-40 to BCNU was not affected by MET depletion ( Figure 6B ). The similar response of mer+ Daoy and mer-SWB-40 to BCNU in MET-HCY+ and the demonstrated association between BCNU sensitivity and MGMT activity in Daoy suggests that this line owes its resistance to alkylating agents to the high levels of MGMT reserves. On the other hand, the marginal effect of MET deprivation on the resistance of SWB-40 to BCNU suggests that down-regulation of MGMT activity is probably the major pathway for the loss of resistance to BCNU and to related alkylating agents in association with the MET-dependence phenotype. An extensive correlation between the down-regulation of MGMT activity by methionine deprivation and the sensitization to BCNU was demonstrated with several mer-, MET-dependent cell lines (Table 3) .
DISCUSSION
Tumours have high MET requirements because of accelerated protein synthesis and transmethylation reactions to yield S-adenosylmethionine, serine, sarcosine, glycine and various phospholipids (Mineura et al, 1993; Kubota et al, 1995) . Twenty-five per cent of human tumours are estimated to be absolutely dependent of MET and cannot use HCY to either proliferate or survive (Guo, 1993) . A greater percentage is expected to be moderately to weakly dependent on MET and to respond, to some extent, to MET deprivation (Hoshiya et al, 1995) . In this regard MET deprivation is an interesting approach to therapy of a variety of tumours assuming that reduction of plasma methionine below the threshold needed to suppress cell proliferation in the tumour can be achieved. As the exogenous MET requirement of METdependent tumour cell lines varies (Halpern et al, 1974; Hoffman and Erbe 1976; Breillout et al, 1987) , the behaviour of tumours in vivo, where MET cannot be completely eliminated, is difficult to predict. Prolonged reduction of plasma MET can be non-toxic in animals if HCY is supplemented to supply normal tissues with a MET precursor. Thus, an eighty per cent reduction of plasma MET has been obtained in athymic mice fed a MET-free diet. Further reduction (approximately 95%) can be achieved with the use of Lmethionine-a-deamino-y-mercaptomethane lyase, also known as methioninase (Lishko et al, 1993) , an enzyme that has been recently cloned and mass produced (Hori et al, 1996) . A combination of MET-depleting diets and methioninase could theoretically cause a decrease in plasma MET to less than 5 gM, which is the threshold for supporting cell proliferation in all MET-dependent tumour cell cultures examined (DM Kokkinakis, unpublished observations).
Three out of eight tumours tested here are strongly dependent on MET and are rapidly and nearly eradicated, mainly as the result of G2 blocks induced by MET deprivation. The rest of the tumours tested, including all gliomas, resisted MET starvation (in the presence of HCY) and were able to survive for several weeks and resume growth when MET was repleated. Prolonged survival, possibly as the result of G, cell cycle blocks of MET-dependent tumour cells is expected to be a major problem in any effort to eradicate tumours based entirely on MET-depleting regimens. In this regard, although MET depletion may be useful in replacing toxic chemotherapeutic treatments, its greater application could be in conjunction with currently used chemotherapeutic agents, as previously suggested (Stem and Hoffman, 1986; Breillout et al, 1987; Goseki et al, 1992) .
A major mechanism of resistance of cells to genotoxic injury, particularly to the formation of the toxic and mutagenic 06-alkylguanine DNA adducts and to subsequent lethal DNA cross-links, is mediated by the DNA repair protein MGMT. This protein, which reverses formation of 06-alkylguanine adducts including those with the potential to react with DNA bases of the opposite strand and form cross-links, is abundant in more than eighty per cent of the human tumours, rendering them resistant to a variety of genotoxic alkylating chemotherapeutic agents (Day et al, 1980; Tsujimura et al, 1987; Dolan et al, 1990) . In many cases, levels of MGMT activity in tumour tissue are well above that of the normal surrounding tissue or of other vital tissues (Gerson et al, 1985) . This is believed to be the main reason for the poor therapeutic index of many chemotherapeutic genotoxic drugs that alkylate the 06-position of guanine used in chemotherapy. Significant increase in the efficacy of alkylating chemotherapeutic drugs, such as BCNU, against MGMT-positive tumours has been obtained with the prior depletion of MGMT activity both in tumour and in normal tissue by O6-benzylguanine and its analogues Schold et al, 1996) . Depletion of MGMT in animals treated with 06-benzylguanine analogues is effective provided that the inhibitor and its active metabolites are present in adequate concentrations to sustain destruction of newly synthesized MGMT (Kroes and Erickson, 1995) . Low levels of MGMT found in MET-HCY+ for several days after reaching a nadir further demonstrate the slow rate of basal transcription of this gene by cells that are apparently blocked in G,. In the simplest scenario, MET withdrawal inhibits transcription but has no effect on the stability of mRNA and protein. A gradually declining MGMT activity therefore reflects the difference between degradation of the protein with a half-life of approximately 20 h and translation of preexisting mRNA, which is also on a decline, with a half-life of approximately 12 h (Kroes and Erickson, 1995) . Resynthesis of protein, mainly from translation of pre-existing mRNA, may influence the kinetics of MGMT decline by increasing the apparent half-lives of the MGMT activity from the expected 20 h up to 48 h depending on the tumour line. A lag period in the decline of MGMT activity observed in H-1944 is probably the result of the ability of this cell line to use HCY and maintain higher levels of endogenous MET than Daoy (data not shown). The mechanism of down-regulation of MGMT activity by MET deprivation could potentially involve changes in the methylation of the gene. Such changes, particularly at the promoter region of the MGMT gene, have already been recognized as having an intimate association with cellular levels in MGMT activity. Thus, a direct correlation between methylation in the body of the gene and MGMT expression has been previously observed (Pieper et al, 1991; Harris et al, 1994; von Wronski and Brent, 1994) , whereas methylation at the 5' promotor region has been associated with complete suppression of the gene (von Wronski et al, 1992; von Wronski and Brent, 1994) . Consistent with the latter correlation, cells expressing high levels of MGMT, such as Daoy and U-138, are not methylated at the SmaI site of the promoter. It is not surprising that the SmaI site remained methylation free under conditions of MET deprivation, although such methylation would be consistent with the observed MGMT suppression. It is still possible that methylation of the promoter region at other sites could be involved in transcriptional suppression as a number of sites with such potential have been identified in tumour cells (Qian et al, 1995) . However, regulation of MGMT activity by hypermethylation of the promoter is not expected to occur in a MET-deficient state, especially in the presence of high levels of HCY which could result in the accumulation of S-adenosylhomocysteine and consequently in the inhibition of DNA methylation and other transmethylation reactions (Johnson and Aswad, 1993) . If MET deprivation regulates MGMT activity by changing the methylation status of the gene, it would be expected that such regulation would be the result of the hypomethylation of the downstream region rather than the methylation of the promoter. The absence of changes in the methylation of the body of the gene indicates that either methylation is not involved in the down-regulation of MGMT by MET deprivation, or changes of the status of methylation are not detected by the methodology used. If methylation of CpG islands is not involved in the down-regulation of MGMT activity in MET-dependent tumours by MET deprivation, it may be because of changes in chromatin structure or transacting factors by mechanisms not yet identified.
The down-regulation of MGMT by MET deprivation in mer+, MET-dependent tumour cells indicates that MET-dependent tumours are susceptible to MET deprivation not only because of cell cycle blocks, but also because they are sensitized to alkylating agents. Our results indicate that the reduction of MGMT activity is not strictly dependent on the degree of sensitivity of the tumour to MET deprivation. Tumour cells that are moderately MET dependent and resist MET withdrawal, such as U-138, lose their MGMT activity nearly as fast as fully MET-dependent lines, such as the H-1623 and Daoy. This is particularly important in vivo where MET levels cannot be indefinitely suppressed to near zero levels. Thus, MET-depleting regimens, dietary or enzymatic, could be used to arrest or reverse tumour growth long enough to suppress MGMT activity. Elimination of a substantial portion of the tumour mass as a result of G2 blocks may facilitate further treatment of the tumour, but it is not an absolute requirement for the employment of chemotherapy aiming to kill cells sensitized to DNA damage. Additional mechanisms of resistance may also have been compromised by the lack of MET, which could explain the reported susceptibility of MET-dependent cells to the combination of MET depletion with antineoplastic drugs other than alkylating agents. These results further support the use of MET depletion regimens in combination with genotoxic drugs for the treatment of MET-dependent, mer+ tumours.
